Search

We aimed to evaluate the diagnostic potential of dual-time-point imaging with positron emission tomography (PET) using O-(2-[(18)F]fluoroethyl)-L-tyrosine ((18)F-FET) for non-invasive grading of cerebral gliomas compared with a dynamic approach.Thirty-six patients with histologically confirmed cerebral gliomas (21 primary, 15 recurrent; 24 high-grade, 12 low-grade) underwent dynamic PET from 0 to 50 min post-injection (p.i.) of (18)F-FET, and additionally from 70 to 90 min p.i. Mean tumour-to-brain ratios (TBRmean) of (18)F-FET uptake were determined in early (20-40 min p.i.) and late (70-90 min p.i.) examinations. Time-activity curves (TAC) of the tumours from 0 to 50 min after injection were assigned to different patterns. The diagnostic accuracy of changes of (18)F-FET uptake between early and late examinations for tumour grading was compared to that of curve pattern analysis from 0 to 50 min p.i. of (18)F-FET.The diagnostic accuracy of changes of the TBRmean of (18)F-FET PET uptake between early and late examinations for the identification of HGG was 81% (sensitivity 83%; specificity 75%; cutoff - 8%; p 0.001), and 83% for curve pattern analysis (sensitivity 88%; specificity 75%; p 0.001).Dual-time-point imaging of (18)F-FET uptake in gliomas achieves diagnostic accuracy for tumour grading that is similar to the more time-consuming dynamic data acquisition protocol.• Dual-time-point imaging is equivalent to dynamic FET PET for grading of gliomas. • Dual-time-point imaging is less time consuming than dynamic FET PET. • Costs can be reduced due to higher patient throughput. • Reduced imaging time increases patient comfort and sedation might be avoided. • Quicker image interpretation is possible, as no curve evaluation is necessary.

88 Objectives To determine if 18F-FDG (FDG) could replace 67Ga (Ga) for differentiating acute interstitial nephritis (AIN) from acute tubular necrosis (ATN). Methods 50 rats were divided into 3 groups: Controls (10), AIN (20) & ATN (20). Half of the animals in each group were studied with FDG & half with Ga. AIN animals were imaged 14 days after a single injection of 150 mg/kg puromycin aminonucleoside. ATN animals were imaged 8 days after intraperitoneal injection of 6 mg/kg cisplatin. FDG imaging was performed on a micro-PET system 45 min after tail vein injection of 7.4 MBq FDG. Kidney SUV’s were determined. After imaging, organs were removed & kidney/spine tissue counting ratios generated. Renal tissue samples were evaluated by a pathologist for evidence of cellular infiltration. Ga imaging was performed 48 hr after tail vein injection of 3.7 MBq Ga. Static images were acquired at maximum magnification (zoom = 2.19, 5.9 mm/pixel) with a pinhole collimator for 10 min. Regions of interest were drawn around kidneys & adjacent lumbar spine; kidney:spine image count ratios were generated. An experienced Nuclear physician interpreted all images visually. Results For FDG, AIN & ATN SUV’s were significantly higher than Control SUVs, but similar to each other (Table). Tissue analysis results were similar. The reader could distinguish FDG AIN & ATN from Controls, but not from each other. For Ga, kidney:spine ratios were significantly higher for AIN than ATN & Controls, which were similar to each other. Tissue analysis results were similar. The reader could differentiate AIN from ATN & Controls, but not ATN from Controls. Cellular infiltration was predominantly mononuclear, & was significantly higher in AIN than in ATN & Controls (2.3±0.5 versus 0.6±0.5 cells, p=0.002). Conclusions The results indicate that FDG-PET cannot replace Ga for differentiating acute interstitial nephritis from acute tubular necrosis.

Background Despite an increasing number of O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) PET studies in supratentorial gliomas, studies regarding the usefulness of 18F-FET PET in brainstem and spinal cord gliomas to date remain scarce. Methods Thirty-six 18F-FET PET scans were performed in 29 patients with brainstem (n = 29 scans) or spinal cord glioma (n = 7 scans). In 32 of 36 PET scans, a dynamic acquisition was performed. Fifteen scans in 15 patients were performed to assess newly diagnosed lesions, and 21 scans were obtained during follow-up: for diagnosing tumor progression (n = 15 scans in 14 patients) as well as for treatment monitoring (n = 6 scans in 3 patients). Four patients underwent additional serial scans (range, 1-2), and 3 of these 4 patients were examined for more than one indication. Maximum and mean tumor/brain ratios (TBRmax/mean) of 18F-FET uptake (20-40 min post injection) as well as kinetic 18F-FET uptake parameters were determined. Final diagnoses were confirmed histologically (54%) or by clinical follow-up (46%). Results In all newly diagnosed high-grade (n = 3 patients) and in 5 of 11 patients with low-grade gliomas, 18F-FET uptake was increased (TBRmax ≥2.5 and/or TBRmean ≥1.9). In 2 patients with newly diagnosed gliomas without MR contrast enhancement, 18F-FET PET nevertheless showed increased metabolism. At suspected progression, the combination of TBRs with kinetic 18F-FET parameters correctly identified presence or absence of progressive disease in 9 of 11 patients (82%). Conclusions This preliminary study suggests that 18F-FET PET adds valuable diagnostic information in brainstem and spinal cord glioma, particularly when the diagnostic information derived from MRI is equivocal.